Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ting Therapeutics, Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners, indicating a diversified prosecution environment where each pending matter is reviewed by a different individual. This distribution requires a broad strategy to address the varying perspectives of multiple USPTO officials.
The portfolio spans multiple art units, matching the number of examiners and pending actions. This one-to-one ratio between actions, examiners, and art units suggests that each matter is isolated within its own administrative silo. The busiest examiner, WELLS, LAUREN QUINLAN, is responsible for 1 pending office action, reflecting a perfectly even workload distribution where no single examiner holds more than one action.
With the pending actions spread across many distinct art units, the company must navigate the specific guidelines of multiple specialized groups. The presence of many distinct examiners for the pending actions increases the variability of the prosecution process. Practitioners should prepare for unique examiner styles rather than a centralized negotiation strategy for the 4 pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +60.1% |
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| HOWELL, THEODORE R | 1 | 66.9% | +25.2% |
| CHONG, YONG SOO | 1 | 43.8% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18792993 | Composition and Methods for the Prevention of Aminoglycoside Toxicity | RAO, SAVITHA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18200148 | Methods for the Prevention and Treatment of Hearing Loss | CHONG, YONG SOO | 80d overdue |
| 18888396 | Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir | WELLS, LAUREN QUINLAN | — |
| 18792993 | Composition and Methods for the Prevention of Aminoglycoside Toxicity | RAO, SAVITHA M | — |
| 18676439 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | HOWELL, THEODORE R | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1691 | 1 |
| 1628 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18888396 | Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir | WELLS, LAUREN QUINLAN | 1622 | §102§103DP | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18792993 | Composition and Methods for the Prevention of Aminoglycoside Toxicity | RAO, SAVITHA M | 1691 | §102§103 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18676439 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | HOWELL, THEODORE R | 1628 | §103DP | Non-Final OA | — | Pending | May 28, 2024 |
| 18200148 | Methods for the Prevention and Treatment of Hearing Loss | CHONG, YONG SOO | 1623 | §102 | Final Rejection | 80d overdue | Pending | May 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTing Therapeutics, Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
Lauren Quinlan Wells has the most, with 1 of Ting Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.